# Timo Atula

## List of Publications by Year in Descending Order

**Source:** https://exaly.com/author-pdf/5535018/timo-atula-publications-by-year.pdf
**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| | | | |
|---|---|---|---|
| 73 papers | 1,675 citations | 21 h-index | 39 g-index |
| 80 ext. papers | 1,896 ext. citations | 3.6 avg, IF | 4.13 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 73 | Tumour-infiltrating lymphocytes in oropharyngeal cancer: a validation study according to the criteria of the International Immuno-Oncology Biomarker Working Group.. *British Journal of Cancer*, **2022**, | 8.7 | 2 |
| 72 | Ear canal and middle-ear tumors: a single-institution series of 87 patients.. *Acta Oto-Laryngologica*, **2022**, 1-8 | 1.6 | |
| 71 | The presence of herpesviruses in malignant but not in benign or recurrent pleomorphic adenomas. *Tumor Biology*, **2021**, 43, 249-259 | 2.9 | 1 |
| 70 | Prognostic Value of Apparent Diffusion Coefficient in Oropharyngeal Carcinoma. *Clinical Neuroradiology*, **2021**, 31, 1037-1048 | 2.7 | 1 |
| 69 | Challenges in diagnosing head and neck cancer in primary health care. *Annals of Medicine*, **2021**, 53, 26-33 | 3.5 | 0 |
| 68 | Three-Dimensional Presentation of Tumor Histopathology: A Model Using Tongue Squamous Cell Carcinoma. *Diagnostics*, **2021**, 11, | 3.8 | 2 |
| 67 | Additive Manufacturing of Resected Oral and Oropharyngeal Tissue: A Pilot Study. *International Journal of Environmental Research and Public Health*, **2021**, 18, | 4.6 | 1 |
| 66 | Factors influencing patient and health care delays in Oropharyngeal Cancer. *Journal of Otolaryngology - Head and Neck Surgery*, **2020**, 49, 22 | 5.4 | 3 |
| 65 | In HPV-negative oropharyngeal squamous cell carcinoma, elevated toll-like receptor 2 immunoexpression may increase the risk of disease-specific mortality. *Oral Oncology*, **2020**, 107, 104778 | 4.4 | 1 |
| 64 | Sclerosing sialadenitis of the submandibular gland is rarely an immunoglobulin G4-related disease in the Finnish population. *Modern Pathology*, **2020**, 33, 551-559 | 9.8 | 3 |
| 63 | Preoperative evaluation and treatment consideration of parotid gland tumors. *Laryngoscope Investigative Otolaryngology*, **2020**, 5, 694-702 | 2.8 | 3 |
| 62 | Expression and Role of E-Cadherin, Catenin, and Vimentin in Human Papillomavirus-Positive and Human Papillomavirus-Negative Oropharyngeal Squamous Cell Carcinoma. *Journal of Histochemistry and Cytochemistry*, **2020**, 68, 595-606 | 3.4 | 5 |
| 61 | Reply to "Do not de-escalate oncology care in oropharyngeal cancer routinely". *Head and Neck*, **2020**, 42, 145-146 | 4.2 | |
| 60 | The expression and prognostic value of stem cell markers Bmi-1, HESC5:3, and HES77 in human papillomavirus-positive and -negative oropharyngeal squamous cell carcinoma. *Tumor Biology*, **2019**, 41, 1010428319840473 | 2.9 | 3 |
| 59 | Management of clinically N0 neck in oropharyngeal carcinoma. *European Archives of Oto-Rhino-Laryngology*, **2019**, 276, 1205-1210 | 3.5 | 2 |
| 58 | Total laryngopharyngectomy with circumferential reconstruction: Helsinki institutional study. *European Archives of Oto-Rhino-Laryngology*, **2019**, 276, 2577-2584 | 3.5 | 1 |
| 57 | Repeatedly recurring pleomorphic adenoma: a therapeutic challenge. *Acta Otorhinolaryngologica Italica*, **2019**, 39, 156-161 | 2.8 | 12 |

| | | | |
|---|---|---|---|
| 56 | De-escalation of post-treatment surveillance in oropharyngeal cancer. *Head and Neck*, **2019**, 41, 1457-1462 | 4.2 | 4 |
| 55 | MMP-7 expression may influence the rate of distant recurrences and disease-specific survival in HPV-positive oropharyngeal squamous cell carcinoma. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2018**, 472, 975-981 | 5.1 | 3 |
| 54 | Expression of hormone receptors in oropharyngeal squamous cell carcinoma. *European Archives of Oto-Rhino-Laryngology*, **2018**, 275, 1289-1300 | 3.5 | 7 |
| 53 | Submandibular gland cancer: Specific features and treatment considerations. *Head and Neck*, **2018**, 40, 154-162 | 4.2 | 16 |
| 52 | Treponema denticola chymotrypsin-like protease as associated with HPV-negative oropharyngeal squamous cell carcinoma. *British Journal of Cancer*, **2018**, 119, 89-95 | 8.7 | 13 |
| 51 | Causes for delay before specialist consultation in head and neck cancer. *Acta Oncologica*, **2018**, 57, 1677-1686 | 3.2 | 9 |
| 50 | Epidemiological and treatment-related factors contribute to improved outcome of oropharyngeal squamous cell carcinoma in Finland. *Acta Oncologica*, **2018**, 57, 541-551 | 3.2 | 14 |
| 49 | Multiple cranial nerve injuries and neck abscesses caused by a transorally penetrating organic stick. *BMJ Case Reports*, **2018**, 2018, | 0.9 | 2 |
| 48 | Complications after surgery for benign parotid gland neoplasms: A prospective cohort study. *Head and Neck*, **2017**, 39, 170-176 | 4.2 | 45 |
| 47 | Is p16 an adequate surrogate for human papillomavirus status determination?. *Current Opinion in Otolaryngology and Head and Neck Surgery*, **2017**, 25, 108-112 | 2 | 8 |
| 46 | Changing trends in the management of the neck in oropharyngeal squamous cell carcinoma. *Head and Neck*, **2017**, 39, 1412-1420 | 4.2 | 6 |
| 45 | Predictive factors and treatment outcome of laryngeal carcinoma recurrence. *Head and Neck*, **2017**, 39, 555-563 | 4.2 | 13 |
| 44 | Preoperative evaluation and surgical planning of submandibular gland tumors. *Head and Neck*, **2017** , 39, 1071-1077 | 4.2 | 18 |
| 43 | Toll-like receptor 5 and 7 expression may impact prognosis of HPV-positive oropharyngeal squamous cell carcinoma patients. *Cancer Immunology, Immunotherapy*, **2017**, 66, 1619-1629 | 7.4 | 25 |
| 42 | Prospective experience of percutaneous endoscopic gastrostomy tubes placed by otorhinolaryngologist-head and neck surgeons: safe and efficacious. *European Archives of Oto-Rhino-Laryngology*, **2017**, 274, 3971-3976 | 3.5 | 1 |
| 41 | Laryngeal cancer in Finland: A 5-year follow-up study of 366 patients. *Head and Neck*, **2016**, 38, 36-43 | 4.2 | 35 |
| 40 | Boron Neutron Capture Therapy in the Treatment of Recurrent Laryngeal Cancer. *International Journal of Radiation Oncology Biology Physics*, **2016**, 95, 404-410 | 4 | 18 |
| 39 | Toll-like receptors 2, 4, and 9 in primary, metastasized, and recurrent oral tongue squamous cell carcinomas. *Journal of Oral Pathology and Medicine*, **2016**, 45, 338-45 | 3.3 | 12 |

| | | | |
|---|---|---|---|
| 38 | Association of multiple sclerosis and sudden sensorineural hearing loss. *Multiple Sclerosis Journal - Experimental, Translational and Clinical*, **2016**, 2, 2055217316652155 | 2 | 16 |
| 37 | Intracranial Suppurative Complications of Sinusitis. *Scandinavian Journal of Surgery*, **2016**, 105, 254-262 | 3.1 | 18 |
| 36 | Toll-like receptors -4 and -5 in oral and cutaneous squamous cell carcinomas. *Journal of Oral Pathology and Medicine*, **2015**, 44, 258-65 | 3.3 | 16 |
| 35 | MMP-7, MMP-8, and MMP-9 in oral and cutaneous squamous cell carcinomas. *Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology*, **2015**, 119, 459-67 | 2 | 16 |
| 34 | Expression of toll-like receptors in HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma--an in vivo and in vitro study. *Tumor Biology*, **2015**, 36, 7755-64 | 2.9 | 20 |
| 33 | Predictive role of Toll-like receptors 2, 4, and 9 in oral tongue squamous cell carcinoma. *Oral Oncology*, **2015**, 51, 96-102 | 4.4 | 28 |
| 32 | Toll-like receptor 9 mediates invasion and predicts prognosis in squamous cell carcinoma of the mobile tongue. *Journal of Oral Pathology and Medicine*, **2015**, 44, 571-7 | 3.3 | 19 |
| 31 | Developing a Registry for Complications in Otorhinolaryngologic Surgery: Tonsil Surgery as a Pilot Cohort. *Otolaryngology - Head and Neck Surgery*, **2015**, 153, 34-40 | 5.5 | 1 |
| 30 | Matrix metalloproteinase-7 and matrix metalloproteinase-25 in oral tongue squamous cell carcinoma. *Head and Neck*, **2014**, 36, 1783-8 | 4.2 | 18 |
| 29 | Different Toll-Like Receptor Expression Patterns in Progression toward Cancer. *Frontiers in Immunology*, **2014**, 5, 638 | 8.4 | 20 |
| 28 | Epithelial and stromal syndecan-1 and -2 are distinctly expressed in oral- and cutaneous squamous cell carcinomas. *Journal of Oral Pathology and Medicine*, **2013**, 42, 389-95 | 3.3 | 14 |
| 27 | Prognostic significance of matrix metalloproteinase-2, -8, -9, and -13 in oral tongue cancer. *Journal of Oral Pathology and Medicine*, **2012**, 41, 394-9 | 3.3 | 43 |
| 26 | High CIP2A immunoreactivity is an independent prognostic indicator in early-stage tongue cancer. *British Journal of Cancer*, **2011**, 104, 1890-5 | 8.7 | 46 |
| 25 | Bmi-1 expression predicts prognosis in squamous cell carcinoma of the tongue. *British Journal of Cancer*, **2010**, 102, 892-7 | 8.7 | 91 |
| 24 | Micrometastases and isolated tumour cells in sentinel lymph nodes in oral and oropharyngeal squamous cell carcinoma. *European Journal of Surgical Oncology*, **2009**, 35, 532-8 | 3.6 | 31 |
| 23 | Sentinel lymph node biopsy as an alternative to wait and see policy in patients with small T1 oral cavity squamous cell carcinoma. *Acta Oto-Laryngologica*, **2008**, 128, 98-102 | 1.6 | 16 |
| 22 | Sentinel lymph node biopsy or elective neck dissection for patients with oral squamous cell carcinoma?. *European Archives of Oto-Rhino-Laryngology*, **2008**, 265 Suppl 1, S13-7 | 3.5 | 17 |
| 21 | How many sentinel nodes should be harvested in oral squamous cell carcinoma?. *European Archives of Oto-Rhino-Laryngology*, **2008**, 265 Suppl 1, S19-23 | 3.5 | 17 |

| | | | |
|---|---|---|---|
| 20 | Boron neutron capture therapy in the treatment of locally recurred head and neck cancer. *International Journal of Radiation Oncology Biology Physics*, **2007**, 69, 475-82 | 4 | 104 |
| 19 | Predictive value of histopathologic parameters in early squamous cell carcinoma of oral tongue. *Oral Oncology*, **2007**, 43, 1007-13 | 4.4 | 54 |
| 18 | Elective neck treatment versus observation in patients with T1/T2 N0 squamous cell carcinoma of oral tongue. *Oral Oncology*, **2006**, 42, 96-101 | 4.4 | 120 |
| 17 | Sparing of the submandibular glands by intensity modulated radiotherapy in the treatment of head and neck cancer. *Radiotherapy and Oncology*, **2006**, 78, 270-5 | 5.3 | 125 |
| 16 | Erratum to "Sparing of the submandibular glands by intensity modulated radiotherapy in the treatment of head and neck cancer" [Radiother. Oncol. 78 (2006) 270-275]. *Radiotherapy and Oncology*, **2006**, 80, 107-8 | 5.3 | 5 |
| 15 | Cyclooxygenase-2 expression in squamous cell carcinoma of the oral cavity and pharynx: Association to p53 and clinical outcome. *Oncology Reports*, **2006**, 16, 485 | 3.5 | 4 |
| 14 | Sentinel lymph node mapping using SPECT-CT fusion imaging in patients with oral cavity squamous cell carcinoma. *European Archives of Oto-Rhino-Laryngology*, **2006**, 263, 1008-12 | 3.5 | 39 |
| 13 | Pharyngocutaneous fistula following total laryngectomy: a single institution's 10-year experience. *European Archives of Oto-Rhino-Laryngology*, **2006**, 263, 1127-30 | 3.5 | 46 |
| 12 | Intensity modulated radiotherapy for head and neck cancer: evidence for preserved salivary gland function. *Radiotherapy and Oncology*, **2005**, 74, 251-8 | 5.3 | 126 |
| 11 | The MDM2 promoter polymorphism SNP309T-->G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. *Journal of Medical Genetics*, **2005**, 42, 694-8 | 5.8 | 97 |
| 10 | Sentinel lymph node biopsy in oral cavity squamous cell carcinoma without clinically evident metastasis. *Head and Neck*, **2004**, 26, 16-21 | 4.2 | 47 |
| 9 | Biweekly escalated, accelerated hyperfractionated radiotherapy with concomitant single-dose mitomycin C results in a high rate of local control in advanced laryngeal and hypopharyngeal cancer. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2004**, 27, 589-04 | 2.7 | 3 |
| 8 | Tenascin-C expression and its prognostic significance in oral and pharyngeal squamous cell carcinoma. *Anticancer Research*, **2003**, 23, 3051-6 | 2.3 | 22 |
| 7 | Cartilage invasion of laryngeal cancer detected by magnetic resonance imaging. *European Archives of Oto-Rhino-Laryngology*, **2001**, 258, 272-5 | 3.5 | 16 |
| 6 | Complications of acute sinusitis in children. *Acta Oto-Laryngologica*, **2000**, 543, 154-7 | 1.6 | 9 |
| 5 | Otitis media as a sign of Wegener's granulomatosis in childhood. *Acta Oto-Laryngologica*, **2000**, 543, 48-50 | 1.06 | 1 |
| 4 | Human papillomavirus, Epstein-Barr virus, human herpesvirus 8 and human cytomegalovirus involvement in salivary gland tumours. *Oral Oncology*, **1998**, 34, 391-5 | 4.4 | 33 |
| 3 | The evaluation and treatment of the neck in carcinoma of the oral cavity. *Acta Oto-Laryngologica*, **1997**, 529, 223-5 | 1.6 | 7 |

| | | | |
|---|---|---|---|
| 2 | Fine-needle aspiration biopsy in the diagnosis of parotid gland lesions: evaluation of 438 biopsies. *Diagnostic Cytopathology*, **1996**, 15, 185-90 | 1.4 | 56 |
| 1 | Basal cell adenocarcinoma of the parotid gland: a case report and review of the literature. *Journal of Laryngology and Otology*, **1993**, 107, 862-4 | 1.8 | 24 |